Neuren Pharmaceuticals Limited
NURPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $217 | $232 | $15 | $3 |
| % Growth | -6.5% | 1,493.7% | 355.2% | – |
| Cost of Goods Sold | $33 | $27 | $0 | $0 |
| Gross Profit | $184 | $205 | $15 | $3 |
| % Margin | 84.8% | 88.5% | 99.9% | 99.7% |
| R&D Expenses | $33 | $27 | $13 | $10 |
| G&A Expenses | $5 | $6 | $3 | $2 |
| SG&A Expenses | $5 | $6 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $38 | $33 | $16 | $11 |
| Operating Income | $146 | $172 | -$2 | -$18 |
| % Margin | 67.4% | 74.4% | -11% | -555.2% |
| Other Income/Exp. Net | $37 | $33 | $1 | $10 |
| Pre-Tax Income | $183 | $205 | -$1 | -$8 |
| Tax Expense | $41 | $48 | -$1 | $0 |
| Net Income | $142 | $157 | $0 | -$8 |
| % Margin | 65.5% | 67.7% | 1.3% | -243.8% |
| EPS | 1.09 | 1.24 | 0.002 | -0.066 |
| % Growth | -12.1% | 82,566.7% | 102.3% | – |
| EPS Diluted | 1.09 | 1.2 | 0.001 | -0.066 |
| Weighted Avg Shares Out | 131 | 127 | 126 | 118 |
| Weighted Avg Shares Out Dil | 131 | 131 | 129 | 118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $6 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $179 | $199 | -$1 | -$8 |
| % Margin | 82.6% | 85.9% | -5% | -257.3% |